Cathie Wood’s Adaptive Biotechnologies ADPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$44.8M Sell
2,090,306
-2,663
-0.1% -$40.8K 0.29% 64
2026
Q1
$29.1M Sell
2,092,969
-45,991
-2% -$733K 0.23% 70
2025
Q4
$34.7M Sell
2,138,960
-1,026,676
-32% -$16.8M 0.23% 68
2025
Q3
$47.4M Sell
3,165,636
-850,849
-21% -$10.4M 0.28% 60
2025
Q2
$46.8M Sell
4,016,485
-3,716,085
-48% -$33.8M 0.34% 48
2025
Q1
$57.5M Sell
7,732,570
-1,691,504
-18% -$13M 0.58% 36
2024
Q4
$56.5M Sell
9,424,074
-2,177,060
-19% -$12M 0.47% 38
2024
Q3
$59.4M Buy
11,601,134
+189,134
+2% +$824K 0.54% 35
2024
Q2
$41.3M Buy
11,412,000
+850,704
+8% +$2.7M 0.37% 46
2024
Q1
$33.9M Sell
10,561,296
-2,245,217
-18% -$8.69M 0.23% 63
2023
Q4
$62.8M Buy
12,806,513
+1,297,205
+11% +$5.92M 0.37% 41
2023
Q3
$62.7M Buy
11,509,308
+1,055,556
+10% +$6.98M 0.48% 37
2023
Q2
$70.1M Buy
10,453,752
+1,248,627
+14% +$9.28M 0.46% 35
2023
Q1
$81.3M Buy
9,205,125
+3,880
+0% +$34.2K 0.56% 32
2022
Q4
$70.3M Sell
9,201,245
-135,374
-1% -$1.05M 0.61% 33
2022
Q3
$66.5M Buy
9,336,619
+563,601
+6% +$5.31M 0.46% 40
2022
Q2
$68.6M Buy
8,773,018
+1,063,352
+14% +$9.35M 0.41% 46
2022
Q1
$107M Buy
7,709,666
+2,011,798
+35% +$31.6M 0.45% 40
2021
Q4
$160M Buy
5,697,868
+841,447
+17% +$25.8M 0.48% 42
2021
Q3
$165M Buy
4,856,421
+489,444
+11% +$17.7M 0.4% 53
2021
Q2
$178M Buy
4,366,977
+893,067
+26% +$34.7M 0.33% 66
2021
Q1
$140M Buy
3,473,910
+1,928,207
+125% +$104M 0.28% 74
2020
Q4
$91.4M Buy
1,545,703
+660,981
+75% +$34.1M 0.24% 75
2020
Q3
$43M Buy
884,722
+575,584
+186% +$24.2M 0.26% 61
2020
Q2
$15M Buy
+309,138
New +$11.3M 0.16% 70

Other funds holding ADPT

Cathie Wood's ADPT Position: Q2 2026 in Review

Cathie Wood reduced its Adaptive Biotechnologies (ADPT) stake by 0.13% in Q2 2026, selling an estimated $40.8K and leaving 2,090,306 shares worth $44.8M. The position accounts for 0.29% of the portfolio, ranked #64.

Cathie Wood first reported a position in ADPT in Q2 2020 and has held it in 25 quarters since. The position peaked at $178M in Q2 2021. 298 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Cathie Wood held 2,090,306 shares of Adaptive Biotechnologies worth $44.8M as of Q2 2026.
  • Cathie Wood sold 2,663 Adaptive Biotechnologies shares in Q2 2026, an estimated $40.8K.
  • Adaptive Biotechnologies made up 0.29% of Cathie Wood's portfolio in Q2 2026, its #64 holding.
  • Cathie Wood first reported a position in Adaptive Biotechnologies in Q2 2020 and has held it in 25 quarters since.
  • Cathie Wood's Adaptive Biotechnologies position peaked at $178M in Q2 2021.
  • 298 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on ARK Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.